Intuitive Surgical, Inc. (NASDAQ:ISRG) Stake Increased by First National Trust Co

First National Trust Co increased its stake in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 3.8% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 3,127 shares of the medical equipment provider’s stock after buying an additional 115 shares during the period. First National Trust Co’s holdings in Intuitive Surgical were worth $1,055,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Baystate Wealth Management LLC increased its stake in shares of Intuitive Surgical by 150.0% in the fourth quarter. Baystate Wealth Management LLC now owns 75 shares of the medical equipment provider’s stock worth $25,000 after buying an additional 45 shares during the last quarter. MCF Advisors LLC increased its stake in Intuitive Surgical by 108.1% during the fourth quarter. MCF Advisors LLC now owns 77 shares of the medical equipment provider’s stock valued at $26,000 after purchasing an additional 40 shares during the last quarter. Atticus Wealth Management LLC increased its stake in Intuitive Surgical by 85.4% during the fourth quarter. Atticus Wealth Management LLC now owns 89 shares of the medical equipment provider’s stock valued at $30,000 after purchasing an additional 41 shares during the last quarter. OFI Invest Asset Management bought a new stake in Intuitive Surgical during the third quarter valued at $25,000. Finally, Headinvest LLC bought a new stake in Intuitive Surgical during the third quarter valued at $28,000. Institutional investors own 83.64% of the company’s stock.

Analysts Set New Price Targets

Several research firms have weighed in on ISRG. Wells Fargo & Company boosted their target price on shares of Intuitive Surgical from $363.00 to $416.00 and gave the company an “overweight” rating in a research note on Friday, January 19th. Barclays boosted their target price on shares of Intuitive Surgical from $385.00 to $430.00 and gave the company an “overweight” rating in a research note on Thursday, January 25th. Mizuho boosted their target price on shares of Intuitive Surgical from $350.00 to $390.00 and gave the company a “neutral” rating in a research note on Thursday, January 25th. Royal Bank of Canada boosted their target price on shares of Intuitive Surgical from $400.00 to $432.00 and gave the company an “outperform” rating in a research note on Wednesday, January 24th. Finally, Jefferies Financial Group boosted their price target on shares of Intuitive Surgical from $365.00 to $375.00 and gave the company a “hold” rating in a report on Friday, April 19th. Five equities research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $396.17.

Intuitive Surgical Trading Up 1.0 %

ISRG stock traded up $3.71 during mid-day trading on Friday, reaching $381.36. 1,028,858 shares of the stock traded hands, compared to its average volume of 1,492,254. Intuitive Surgical, Inc. has a 52-week low of $254.85 and a 52-week high of $403.76. The company has a market cap of $135.27 billion, a P/E ratio of 68.84, a P/E/G ratio of 4.93 and a beta of 1.39. The stock’s fifty day moving average is $385.40 and its 200-day moving average is $349.30.

Intuitive Surgical (NASDAQ:ISRG) last posted its quarterly earnings results on Thursday, April 18th. The medical equipment provider reported $1.50 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.40 by $0.10. Intuitive Surgical had a net margin of 27.16% and a return on equity of 12.91%. The business had revenue of $1.89 billion during the quarter, compared to analyst estimates of $1.87 billion. During the same period in the prior year, the firm earned $1.00 earnings per share. The firm’s revenue was up 11.5% compared to the same quarter last year. Equities research analysts expect that Intuitive Surgical, Inc. will post 4.8 earnings per share for the current year.

Insider Transactions at Intuitive Surgical

In other Intuitive Surgical news, SVP Mark Brosius sold 196 shares of Intuitive Surgical stock in a transaction on Tuesday, March 5th. The stock was sold at an average price of $400.00, for a total transaction of $78,400.00. Following the completion of the transaction, the senior vice president now directly owns 1,842 shares of the company’s stock, valued at $736,800. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other Intuitive Surgical news, Director Alan J. Levy sold 2,000 shares of Intuitive Surgical stock in a transaction on Tuesday, April 23rd. The stock was sold at an average price of $370.70, for a total value of $741,400.00. Following the completion of the transaction, the director now directly owns 25,319 shares of the company’s stock, valued at approximately $9,385,753.30. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Mark Brosius sold 196 shares of Intuitive Surgical stock in a transaction on Tuesday, March 5th. The shares were sold at an average price of $400.00, for a total value of $78,400.00. Following the completion of the transaction, the senior vice president now directly owns 1,842 shares of the company’s stock, valued at $736,800. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 226,928 shares of company stock worth $87,833,828. Insiders own 0.90% of the company’s stock.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.